

## **Shionogi Received “2018 Award for Excellence in Corporate Disclosure” From the Securities Analysts Association of Japan (SAAJ)**

---

**OSAKA, Japan, October 12, 2018** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi received 2018 Award for Excellence in Corporate Disclosure from the Securities Analysts Association of Japan (SAAJ). Shionogi ranked first in the pharmaceuticals sector. This award aims to promote the quality and fairness of corporate disclosure from the view point of securities analysts, which was established by SAAJ in 1995 (<http://www.saa.or.jp/english/research/disclosure.html>).

We are highly evaluated this time with regard to its managements' proactive involvement in IR and its corporate governance clearly indicating KPIs on its growth, efficiency and shareholder return. Also, with regard to our integrated disclosure attitude combining financial and non-financial information in order to improve our corporate value, we were able to receive high evaluation.

Shionogi holds “Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare” as our vision. We aim to continuously keep having balanced dialogues with our all stakeholders such as our shareholders/investors, our customers, our surrounding society and our employees with a view to combining our sustainable growth with our society's sustainable growth. We continuously strive to improve our high-level disclosure even more in order to keep having dialogues that lead to make our corporate value higher.



### **2018 Award for Excellence in Corporate Disclosure**

— Industries —



The Securities Analysts  
Association of Japan

**For Further Information, Contact:**  
Corporate Communications Department  
Shionogi & Co., Ltd.  
Telephone: +81-6-6209-7885

# Press Release



## **Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*